CD274 and cancer: The U.S. Food and Drug Administration has approved several anti-PD1 mAbs (nivolumab, pembrolizumab, cemiplimab, and dostarlimab) and anti-PD-L1 mAbs (atezolizumab, durvalumab, and avelumab) to treat cancer patients at a variety of stages due to their significant clinical benefits.